Polymer Conjugates: Pharmacokinetic Considerations for Design and Development

Clinical Pharmacokinetics

Volumn 27, Issue 4, 1994, Pages 290-306

  Duncan, Ruth ^a,b   Spreafico, Federico ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ASPARAGINASE; CELL SURFACE RECEPTOR; INTERLEUKIN 2; MACROGOL; MELPHALAN; POLYMER; PROTEIN; UNINDEXED DRUG; ZINOSTATIN;

ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; CANCER; CELLULAR DISTRIBUTION; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TARGETING; DRUG THERAPY; ENDOCYTOSIS; HUMAN; IMMUNOGENICITY; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; META ANALYSIS; NONHUMAN; PHARMACEUTICS; PHARMACODYNAMICS; PHARMACOKINETICS; PHARMACOLOGY; PRIORITY JOURNAL; REVIEW; STEREOSPECIFICITY; SUBCUTANEOUS DRUG ADMINISTRATION;

ASPARAGINASE; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMAN; INTERLEUKIN-2; NEOPLASMS; POLYETHYLENE GLYCOLS; POLYMERS; PROTEINS;

EID: 0027987791     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-199427040-00004     Document Type: Review

References (158)

1. Adenosine deaminase deficiency with late onset of recurrent infections: Response to treatment with polyethylene-glycol modified adenosine deaminase
2. Effects of polyethylene glycol substitution on enzyme activity
3. Preparation of a non-immunogenic arginase by covalent attachment of polyethylene glycol
4. Modification of E.coli asparaginase with poly ethylene glycol: disappearance and binding ability to anti-asparaginase serum
5. Toxicity of bilirubin and detoxification by PEG-bilirubin oxidase conjugate
6. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulation life of bovine liver catalase
7. Modifications of amino groups in porcine pancreatic elastase with polyethylene glycol in relation to binding ability towards anti-serum to the enzyme activity
8. Enzyme therapy II. Effect of covalent attachment of polyethylene glycol on biochemical parameters and immunological determinants of beta-glucosidase and α-galactosidase
9. Enzyme therapy 1. Polyethylene glycol: β-glucuronidase conjugates as potential therapeutic agents in acid mucopolysaccharidosis
10. Lipase modified for solubility in organic solvents
11. Some properties of polyethylene glycol:phenylalanine ammonia-lysase adducts
12. Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol
13. Effects of monomethoxypoly(ethyleneglycol) modification of ribonuclease on antibody recognition, substrate accessibility, and conformational stability
14. A non antigenic covalent streptokinase polyethylene glycol complex with plasminogen activator function
15. Preparation of a polyethylene glycol: Superoxide dismutase adduct, and examination of its blood circulating life and anti-inflammatory activity
16. Preparation and properties of polyethylene glycol-trypsin adducts
17. Properties of two urate oxidases modified by the covalent attachment of poly(ethylene glycol)
18. Reduction of plasma urate levels in the cockerel with polyethylene glycol-uricase
19. Immunological responses to conjugates of antigen E in patients with ragweed hay fever
20. Suppression of reaginic antibodies with modified allergens. III. Preparation of tolerogenic conjugates of common allergens with monomethoxypolyethylene glycols of different molecular weights by the mixed anhydride method
21. Modification of human haemoglobin with polyethylene glycol: a new candidate for blood substitute
22. Studies on the effect of PEG-modified urokinase on coagulation-fibrinolysis using beagles
23. Preparation of polyethylene glycol tissue plasminogen activator adducts that retain functional activity: characteristics and behaviour in three animal species
24. Chemical modification of alphathrombin and in vivo characterisation of its anticoagulant activity
25. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats
26. Receptor binding studies of PEG modified GM-CSF with dissociated biological activities
27. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model
28. Modification of batroxobin with activated polyethylene glycol: reduction of binding ability towards anti-batroxobin and retention of defibrinogenation activity in the circulation of preimmunized dogs
29. Antibody response to honey-bee venom and monomethoxy-polyethylene glycolmodified honey-bee venom in mice
30. Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy
31. Alteration of the immunological properties of bovine serum albumin by covalent attachment to polyethylene glycol
32. Bovine collagen modified by PEG
33. Toleragenic polyethylene glycol derivatives of xenogenic monoclonal immunoglobulins
34. A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of Superoxide dismutase, lactoferrin and alpha 2-macroglobulin
35. Synthesis, isolation and characterisation of conjugates of ovalbumin and monomethoxypolyethylene glycol using cyanuric chloride as the coupling agent
36. Cell separation by immunoaffinity partitioning with polyethylene glycol-modified protein A in aqueous polymer two-phase systems
37. Effect of arterial administration of high molecular weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report
38. Chemical modification of Superoxide dismutase. Extension of plasma half-life of the enzyme through its reversible binding to circulating albumin
39. Experimental enzyme therapy: suppression of allergic reactions in preimmunized animals by administration of exogenous enzymes in the form of dextran conjugates
40. The effect of chemical modification of L-asparaginase on its persistence in circulating blood of animals
41. Enhanced plasma persistence of therapeutic enzymes by coupling to soluble dextran
42. Manipulation of the properties of enzymes by covalent attachment to carbohydrate
43. Modification of haemoglobin upon covalent coupling to dextran-enhanced stability against acid denaturation and reduced affinity for haptoglobin
44. Reduction of immunogenicity by covalent modification of murine and rabbit immunoglobulins with oxidised dextrans of low molecular weight
45. Binding of covalent proteins to polysaccharides I. Preparation of soluble glycine-insulin and ampicillin dextran
46. Soluble high molecular weight derivatives of pancreatic trypsin inhibitor; Modification of pancreatic trypsin inhibitor by soluble polysaccharides activated by titanium tetrachloride
47. Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran I: synthesis and characterisation
48. Alteration of biopharmaceutical properties of drugs by their conjugation with water-soluble macromolecules; uricase-dextran conjugate
49. Stabilisation of human b-D-acetylhexoseaminidase A towards proteolytic inactivation by coupling it to poly(vinylpyrrolidone)
50. Application of polyvinylpyrollidone as a carrier for kallikrein
51. Activation of poly[N-(2-hydroxypropyl)methacrylamide] for binding of bioactive molecules 1. Activation with 4-nitrophenyl chloroformate
52. Covalent attachment of chymotrypsin to poly [N-(2-hydroxypropyl) methacrylamide]
53. Biological properties of targetable poly[N-(2-hydroxypropyl)methacrylamide]-antibody conjugates
54. Synthesis and activity of a polymer which contains insulin covalently bound on a copolymer of N-(2-hydroxypropyl)methacrylamide and N-methacryloylglycylglycine 4-nitrolphenyl ester
55. Evaluation of antibody-N-(2-hydroxypropyl)methacrylamide copolymer conjugates as targetable drug-carriers. 2.Body distribution of anti Thy-1.2 antibody, anti-transferrin receptor antibody B3/25 and transferrin conjugates in DBA2 mice and activity of conjugates containing daunomycin against L1210 leukaemia in vivo
56. Improvement of pharmacological properties of protein drugs by tailoring with synthetic polymers
57. Reduced bone marrow toxicity of neocarzinostatin by conjugation with divinylethermaleic acid copolymer
58. Immobilised enzymes as drugs
59. Higher antitumour efficacy of daunomycin when linked to dextran: in vivo and in vitro studies
60. Preclinical trials with combinations and conjugates of T101 monoclonal antibody and doxorubicin
61. Preparation, properties and antileukaemic activity of arabinosylcytosine polysaccharide conjugates
62. 6 conjugates and a preliminary study of their photodynamic effect on mouse splenocytes in vitro
63. Preclinical evaluation of polymer-bound doxorubicin
64. Anticancer agents coupled to N-(2-hydroxypropyl) methacrylamide copolymers. 2. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia
65. Macromolecular prodrugs for use in targeted cancer chemotherapy: Melphalan covalently coupled to N-(2-hydroxypropyl)methacrylamide copolymers
66. Optimisation of macromolecular prodrugs of the antitumour antibiotic adriamycin
67. Changes in the toxicity and therapeutic efficacy of daunorubicin linked with a biodegradable carrier
68. Synthesis and antitumour activity of conjugates of poly (α-malic acid) and 5-fluorouracil bound via ester, amide or carbamoyl bonds
69. Toxicity and antitumour activity against solid tumours of micelle-forming polymeric anticancer drug and its extremely long circulation in blood
70. Pharmacological and therapeutic properties of carrier bound methotrexate against tumour confined to a third space body compartment
71. Comparison of antitumour effects of daunorubicin linked covalently to poly-L-amino acid carriers
72. Receptor-mediated gene delivery and expression in vivo
73. Pharmacologically active polymers. 17.Synthesis and characterisation of polymeric derivatives of the antitumour agent methotrexate
74. Increased effect of doxorubicin linked to pyran copolymer in the intracavity treatment of a human ovarian carcinoma in nude mice
75. Antitumour activity of monomeric and polymeric cyclophosphamide derivative compound with in vitro hydrolysis
76. Drug-polymer conjugates potential for improved chemotherapy
77. Soluble macromolecular carriers for the delivery of antitumour drugs
78. Soluble polymers as targetable drug carriers
79. The therapeutic values of poly(ethylene glycol)-modified proteins
80. Suppression of antibody responses by conjugates of antigens and monomethoxypoly(ethyleneglycol)
81. The uses and properties of PEG-linked proteins
82. The clinical efficacy of poly(ethyleneglycol)-modified proteins
83. Use of functionalized poly(ethylene glycol)s for modification of polypeptides
84. Treatment of adenosine deaminase deficiency with polyethylene glycolmodified adenosine deaminase
85. Clinical pharmacology of polyethylene glycol-asparaginase
86. A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2
87. Superoxide dismutase prevents lipid peroxidation in burned patients
88. Succinimidyl carbonates of polyethylene glycol; useful reactions for preparing protein conjugates
89. Hypouricemic effect of polyethylene glycol modified urate oxidase
90. Tailor-making of protein drugs by polymer conjugation for tumour targeting: a brief review on SMANCS
91. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy
92. Conjugation of poly(sty-rene-co-maleic acid) derivatives to the antitumour protein neocarzinostatin: Pronounced improvements in pharmacological properties
93. A new concept for macromolecular therapeutics in cancer chemotherapy; mechanism of tumoritropic accumulation of proteins and the antitumour agent SMANCS
94. Use of oily contrast medium for selective drug targeting to tumour: enhanced therapeutic effect and X-ray image
95. Structure and properties of pharmacologically active polymers
96. Lysosomotropic agents
97. Selective endocytosis
98. Controlled biodegradability of polymers — key to drug delivery systems
99. Passive tumour targeting of soluble macromolecules and drug conjugates
100. Tumoritropic and lymphotropic principles of macromolecular drugs
101. Pharmacology of Escherichia coli-L-asparaginase polyethylene glycol adduct
102. Characterisation of poly-ethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia
103. Clinical experience with polyethylene glycol-bound E.coli L-asparaginase in patients with multiple recurrences of acute lymphoblastic leukemia
104. A phase II study of polyethylene glycol (PEG) conjugated L-asparaginase in patients with refractory acute leukaemias
105. A Phase II trial of Peg-L-asparaginase in the treatment of non-Hodgkin’s lymphoma
106. The use of polyethylene glycol-conjugated L-asparaginase (PEG-ASP) in pediatric patients with prior hypersensitivity to native L-asparagine
107. High efficacy of monomethoxypolyethylene glycol-L-asparaginase (PEG2-ASP) in two patients with hematological malignancies
108. Antibodies to asparaginase alter pharmacokinetics and decrease enzyme activity in patients on asparaginase therapy
109. Phase II multicenter trials of PEG IL-2 in patients with metastatic renal cell carcinoma (MRCC)
110. Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase
111. Use of polyethyleneglycol modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin’s lymphoma
112. Clinical pharmacokinetics of PEG-superoxide dismutase
113. Perirenal transplant quantitation of free radical scavenger enzyme activity (FRSEA)- the effect of a single dose of PEG-SOD and renal failure
114. Improving the outcome of severe head injury with the oxygen radical scavenger polyethylene glycol-conjugated Superoxide dismutase: a phase II trial
115. Distribution and mechanism of clearance of L-asparaginase (NSC-109229)
116. The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2
117. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells with interleukin-2 or high dose interleukin 2 alone
118. Pharmacokinetics of recombinant interleukin 2 in humans
119. Preparation, in vivo properties, and proposed clinical use of polyoxyethylene-modified tissue plasminogen activator and streptokinase
120. The conjugation of proteins with polyethylene glycol and other proteins. Altering properties of proteins to enhance their therapeutic potential
121. Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo
122. Pharmacokinetic properties of polyethyleneglycol derivatised Superoxide dismutase
123. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers
124. PEG Superoxide dismutase derivatives: anti-inflammatory activity in carrageenan pleurisy in rats
125. Preparation, physical-chemical and pharmocokinetic characterisation of monomethoxypoly(ethylene glycol)-derivatized Superoxide dismutase
126. Schedule dependency of the antitumour activity and toxicity of polyethylene glycol-modified interleukin 2 in murine tumour models
127. Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distributions and rate of excretion after subcutaneous intraperitoneal and intravenous administration to rats
128. Interaction of a cationic N-(2-hydroxypropyl)methacrylamide copolymer with rat liver in vivo
129. Evaluation of poly(glutamic acid, alanine, tyrosine) (1:1:1) as a lung-specific drug delivery system. 1. Biocompatibility and studies on biodistribution in the rat. S.T.P
130. Tyrosinamide residues enhance pinocytic capture of N-(2-hydroxypropyl)-methacrylamide copolymers
131. Preclinical evaluation of polymer-bound doxorubicin
132. Anticancer agents coupled to N-(2-hydroxypropyl) methacrylamide copolymers. 2. Evaluation of daunomycin conjugates in vivo against LI210 leukaemia
133. Macromolecular prodrugs for use in targeted cancer chemotherapy: Melphalan covalently coupled to N-(2-hydroxypropyl)methacrylamide copolymers
134. Degradation of side-chains of N-(2-hydroxypropyl)methacrylamide copolymers by lysosomal thiol-proteinases
135. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B
136. Polymers containing enzymatically degradable bonds, XII
137. Macromolecular prodrugs containing doxorubicin and melanocyte stimulating hormone in vitro and in vivo evaluation against murine melanoma
138. Pharmacokinetics of polymer-bound adriamycin
139. Activity of N-(2-hydroxypropyl)methacrylamide copolymers containing daunomycin against rat tumour model
140. Anticancer agents coupled to N-(hydroxypropyl) methacrylamide copolymers. 2. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia
141. Reduced cardiotoxicity of doxorubicin administered in the form of N-(2-hydroxypropyl)methacrylamide conjugates: an experimental study in the rat
142. Biocompatibility of N-(2-hydroxypropyl)methacrylamide copolymers containing adriamycin. Immunogenicity, effect on haematopoietic stem cells in bone marrow in vivo and effect of mouse splenocytes and human peripheral blood lymphocytes in vitro
143. Selective tumor localisation and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes
144. N-(2-hydroxy-propyl)methacrylamide copolymers with pendant galactosamine residues. Fate after intravenous administration to rats
145. Targeting of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate to the hepatocyte galactose-receptor in mice: visualisation and quantification by gamma scintigraphy as a basis for clinical targeting studies
146. Comparison of the liver subcellular distribution of free daunomycin and that bound to galactosamine targeted N-(2-hydroxypropyl)methacrylamide copolymers following intravenous administration in the rat
147. Pharmacokinetics of a polymeric drug carrier targeted to the hepatocyte galactose receptor